RBC Europe’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

RBC Europe’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$48K	Buy	+650	New	+$48.8K	﹤0.01%	334

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

RBC Europe's XBI Position: Q2 2022 in Review

RBC Europe opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2022: 650 shares worth $48K. The stake represents ﹤0.01% of the portfolio and ranks #334 among its holdings.

706 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

RBC Europe held 650 shares of State Street SPDR S&P Biotech ETF worth $48K as of Q2 2022.
State Street SPDR S&P Biotech ETF was a new RBC Europe position in Q2 2022.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of RBC Europe's portfolio in Q2 2022, its #334 holding.
706 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on RBC Europe's 13F filing for Q2 2022, filed 14 Nov 2022.